The initiation of clinical trials to use anti-IL-7Rα antibodies for the treatment of type 1 diabetes and other autoimmune diseases [18] underscores the necessity to better understand the treatment modalities and mechanisms underlying protection against type 1 diabetes provided by anti-IL-7Rα administration. This evidence concerns the gene IL7R and type 1 diabetes mellitus.